Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 1.56B |
| Revenue (ttm) | -665,000 |
| Net Income (ttm) | -149.28M |
| Shares Out | 109.82M |
| EPS (ttm) | -1.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,105,639 |
| Open | 14.54 |
| Previous Close | 14.49 |
| Day's Range | 14.09 - 15.06 |
| 52-Week Range | 2.60 - 16.96 |
| Beta | -0.33 |
| Analysts | Strong Buy |
| Price Target | 17.43 (+22.75%) |
| Earnings Date | Nov 6, 2025 |
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and t... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for AMLX stock is "Strong Buy." The 12-month stock price target is $17.43, which is an increase of 22.75% from the latest price.
News
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?
New York City-based Commodore Capital bought nearly 4.1 million shares, increasing portfolio value by an estimated $55 million. The position represents 2.7% of 13F reportable assets under management (...
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Shareholders should contact the firm immediately as there may be limited time to enforce your rights. NEW YORK , Nov. 28, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is inves...
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead
California-based TCG Crossover bought 300,000 shares of Amylyx Pharmaceuticals for an estimated $46.8 million in the third quarter. At quarter-end, TCG Crossover reported holding 6.2 million total sha...
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investigation of potential breaches of fiduciary duties by the directors and officers of Amylyx Pharmaceutica...
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. ( AMLX) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Lindsey Allen Justin Klee - Co-Founder, Co-CEO & Director Camille Bedrosian - Chief Medica...
Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial and business results for the third quarter ended September 30, 2025....
Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences.
Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025.
Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) breached their fiduciar...
AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders
Amylyx allegedly misled investors about Relyvrio's demand and growth, hiding high discontinuation rates and a fading launch surge that hurt its viability.
Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,500,000 shares...
Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock.
Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT Company Participants Justin Klee - Co-Founder, Co-CEO & Director Joshu...
Amylyx Pharmaceuticals, Inc. (AMLX) Presents At Citi's Biopharma Back To School Conference Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Citi's Biopharma Back to School Conference September 2, 2025 1:00 PM EDT Company Participants Joshua Cohen - Co-Founder, Co-CEO & Director Justin Klee - Co-...
Amylyx to stop development of rare brain disorder drug after trial failure
Amylyx Pharmaceuticals said on Wednesday it will discontinue development of its experimental drug for a rare brain disorder after the treatment failed to show benefit in a mid-stage trial.
Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP).
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences.
Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Camille L. Bedrosian - Chief Medical Officer James M.
Amylyx (AMLX) Q2 Net Loss Narrows 43%
Amylyx (AMLX) Q2 Net Loss Narrows 43%
Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results.
Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025.
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery
Amylyx Pharmaceuticals, Inc. AMLX on Sunday presented new exploratory analyses from its Phase 2 PREVENT and Phase 2b trials of avexitide—an investigational GLP-1 receptor antagonist—at the Endocrine S...